

1) Status of the notification

Final

2) Issuer

Name GALAPAGOS
Identification number 0466-460-429

3) Reason for the notification

Acquisition or disposal of the control of an undertaking that holds a participating interest in an issuer



4) Notification by

A parent undertaking or a controlling person



5) Persons subject to the notification requirement

Name	Address (for legal entities)
Gilead Sciences, Inc.	1209 Orange Street, Wilmington, DE 19801, USA



6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)



Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

28/12/2019 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

25

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

64.666.802

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Gilead Sciences, Inc.	0	0		0,00%	
Gilead Biopharmaceutics US, LLC		0		0,00%	
Gilead Biopharmaceutics Ireland UC	0	0		0,00%	
Gilead Sciences Ireland UC		0		0,00%	
Gilead Therapeutics A1 Unlimited Company	16.207.477	16.707.477		25,84%	



Subtotal	16.207.477	16.707.477		25,84%	
TOTAL		16.707.477	0	25,84%	0,00%



Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0,00%	

 **The totals** will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	CALCULATE	
	16.707.477	25,84%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Gilead Therapeutics A1 Unlimited Company (address: 70 Sir John Rogerson's Quay, Dublin 2, Ireland) is a direct subsidiary of Gilead Sciences Ireland UC.

Gilead Sciences Ireland UC (address: IDA Business & Technology Park, Carrigtohill, Co. Cork., Ireland) is a direct subsidiary of Gilead Biopharmaceutics Ireland UC.

Gilead Biopharmaceutics Ireland UC (address: 70 Sir John Rogerson's Quay, Dublin 2, Ireland) is a direct subsidiary of Gilead Biopharmaceutics US, LLC.

Gilead Biopharmaceutics US, LLC (address: 333 Lakeside Drive, Foster City, CA 94404 USA) is a direct subsidiary of Gilead Sciences, Inc.

Gilead Sciences, Inc. has no controlling shareholder.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again ^(DD/MM/YYYY) voting rights as of

13) Additional information

This notification is made in connection with a change in the chain of intermediary companies through which the Gilead group holds its shares in Galapagos:

- On 27 December 2019, Gilead Biopharmaceutics US, LLC, a direct subsidiary of Gilead Sciences Inc., acquired control over Gilead Biopharmaceutics Ireland UC.
- On 28 December 2019, Gilead Sciences Ireland UC, a direct subsidiary of Gilead Biopharmaceutics Ireland UC, acquired control over Gilead Therapeutics A1 Unlimited Company.

Done at

On (DD/MM/YYYY)

Name & capacity

Signature

